Mirum Pharmaceuticals Inc. - notizie pubblicate 221 - letture 2.945
MIRUM PHARMACEUTICALS INC.
Statement of Changes in Beneficial Ownership - Form 4
Form 4 check this box if no longer subject to section 16, form 4 or form 5 obligations may continue. see instruction 1(b). united states securities and exchange commission washingt ...
MIRUM PHARMACEUTICALS INC.
Statement of Changes in Beneficial Ownership - Form 4
Form 4 check this box if no longer subject to section 16, form 4 or form 5 obligations may continue. see instruction 1(b). united states securities and exchange commission washingt ...
MIRUM PHARMACEUTICALS INC.
Statement of Changes in Beneficial Ownership - Form 4
Form 4 check this box if no longer subject to section 16, form 4 or form 5 obligations may continue. see instruction 1(b). united states securities and exchange commission washingt ...
MIRUM PHARMACEUTICALS INC.
Initial Statement of Beneficial Ownership - Form 3
Form 3 united states securities and exchange commission washington, d.c. 20549initial statement of beneficial ownership of securities filed pursuant to section 16(a) of the securit ...
MIRUM PHARMACEUTICALS INC.
Statement of Changes in Beneficial Ownership - Form 4
Form 4 check this box if no longer subject to section 16, form 4 or form 5 obligations may continue. see instruction 1(b). united states securities and exchange commission washingt ...
MIRUM PHARMACEUTICALS INC.
Quarterly Report for Quarter Ending March 31, 2023 (Form 10-Q)
United states securities and exchange commission washington, d.c. 20549 form 10-q (mark one) ☒ quarterly report pursuant to section 13 or 15(d) of the securities exchange act of ...
MIRUM PHARMACEUTICALS INC.
Mirum Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Business Update - Form 8-K
Mirum pharmaceuticals reports first quarter 2023 financial results and provides business update - $31.6 million total revenue, including net product sales for livmarli® (maralixib ...
MIRUM PHARMACEUTICALS INC.
Proxy Statement - Form DEF 14A
Table of contents schedule 14a information proxy statement pursuant to section 14(a) of the securities exchange act of 1934 (amendment no. ) filed by the registrant ☒ filed by a ...
MIRUM PHARMACEUTICALS INC.
Additional Proxy Soliciting Materials - Form DEFA14A
Schedule 14a information proxy statement pursuant to section 14(a) of the securities exchange act of 1934 (amendment no. ) filed by the registrant ☒ filed by a party other than t ...
MIRUM PHARMACEUTICALS INC.
Annual Report - Form ARS
The text version of this document is not available. you can access the original document here. attachments original link original document permalink disclaimer mirum pharmaceutical ...
MIRUM PHARMACEUTICALS INC.
Mirum Pharmaceuticals Announces Proposed Convertible Senior Notes Offering - Form 8-K
Mirum pharmaceuticals announces proposed convertible senior notes offering foster city, calif.-(business wire)-april 12, 2023-mirum pharmaceuticals, inc. ("mirum") (nasda ...
MIRUM PHARMACEUTICALS INC.
Mirum Pharmaceuticals Announces Preliminary Unaudited First Quarter 2023 Financial Results - Form 8-K
Mirum pharmaceuticals announces preliminary unaudited first quarter 2023 financial results foster city, calif - april 12, 2023 - mirum pharmaceuticals, inc. (nasdaq: mirm) today an ...
MIRUM PHARMACEUTICALS INC.
Initial Statement of Beneficial Ownership - Form 3
Form 3 united states securities and exchange commission washington, d.c. 20549initial statement of beneficial ownership of securities filed pursuant to section 16(a) of the securit ...
MIRUM PHARMACEUTICALS INC.
Statement of Changes in Beneficial Ownership - Form 4
Form 4 check this box if no longer subject to section 16, form 4 or form 5 obligations may continue. see instruction 1(b). united states securities and exchange commission washingt ...
MIRUM PHARMACEUTICALS INC.
Management Change - Form 8-K
8-k united states securities and exchange commission washington, d.c. 20549 form 8-k current report pursuant to section 13 or 15(d) of the securities exchange act of 1934 date of r ...
Sei un professionista?
Abbiamo ricevuto 2.400 richieste di consulenza, pubblica il tuo profilo premium
per ricevere contatti e acquisire nuovi clienti